Gossamer Bio stock (US38198T1034): Class actions follow Phase 3 trial failure

Gossamer Bio faces multiple securities class action lawsuits after its Phase 3 PROSERA study missed the primary endpoint, triggering an 80% stock plunge on February 23, 2026.

Gossamer Bio Inc. (NASDAQ: GOSS) is confronting several securities class action lawsuits filed by investors alleging misleading disclosures about its Phase 3 PROSERA trial for seralutinib in pulmonary arterial hypertension. The suits target the period from June 16, 2025, to February 20, 2026, following the company's February 23, 2026, announcement that the study failed to meet its primary endpoint of change in six-minute walk distance at week 24. The stock dropped from $2.13 to $0.42 that day, an 80% decline, according to GlobeNewswire as of 05/11/2026.

Lawsuits claim Gossamer knew or disregarded trial design flaws, including patient recruitment and site monitoring issues, particularly at Latin American sites where placebo responses were unusually high. Analysts reacted swiftly: Wedbush downgraded to Neutral on February 24, 2026, cutting its price target from $6 to $1, citing a p-value of 0.0320 against the 0.025 threshold and regional placebo anomalies, per GlobeNewswire as of 05/11/2026. Oppenheimer followed on March 5, 2026, reducing its target from $12 to $3.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gossamer Bio, Inc.
• Sector/industry: Biopharmaceuticals
• Headquarters/country: San Diego, USA
• Core markets: United States, global
• Key revenue drivers: Clinical-stage therapies for immuno-inflammatory diseases
• Home exchange/listing venue: Nasdaq (GOSS)
• Trading currency: USD

Gossamer Bio Inc.: core business model

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company developing therapies targeting the immune system to treat immuno-inflammatory and other diseases, including pulmonary arterial hypertension (PAH). Headquartered in San Diego, California, the firm focuses on small-molecule product candidates like seralutinib, a PDGFR, CSF1R, and c-KIT inhibitor delivered via dry powder inhalation for PAH, according to Newsfile as of 05/11/2026.

The company's pipeline emphasizes precision immunology, with PAH as a key area given its impact on US patients—over 40,000 Americans live with the condition, per industry data. Gossamer's approach differentiates via inhaled delivery to minimize systemic side effects.

Main revenue and product drivers for Gossamer Bio Inc.

Gossamer remains pre-revenue, relying on cash reserves and financing for clinical trials. Seralutinib represents the primary value driver, with the PROSERA Phase 3 trial enrolling 265 patients across global sites to assess walk distance improvement. The trial's failure has raised questions on future funding and pipeline viability for US investors tracking biotech volatility.

Other candidates include GB002 for asthma and GB004 for idiopathic pulmonary fibrosis, though progress lags behind seralutinib. Nasdaq listing exposes the stock to US institutional interest in rare disease therapies.

Industry trends and competitive position

The PAH market, valued at $7.3 billion globally in 2023 per Statista data published 2024, grows amid new therapies but faces high trial failure rates. Competitors like Johnson & Johnson and Merck hold approved drugs, while Gossamer's inhaled tyrosine kinase inhibitor aimed to carve a niche. US investors note PAH's orphan drug status offers potential FDA incentives if reproven.

Why Gossamer Bio Inc. matters for US investors

As a Nasdaq-listed biotech, Gossamer Bio provides US retail investors exposure to high-risk, high-reward PAH innovation. The sector's ties to US healthcare spending—PAH treatments cost $100,000+ annually per patient—underscore relevance amid Medicare dynamics.

Conclusion

Gossamer Bio Inc. grapples with class action fallout from the PROSERA trial miss, which erased most of its market value in one session. Analyst downgrades reflect eroded confidence in trial execution, while lawsuits probe disclosure practices. US investors monitoring biotech will watch funding updates and pipeline pivots for signs of recovery potential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.